CL2013001324A1 - Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer. - Google Patents

Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.

Info

Publication number
CL2013001324A1
CL2013001324A1 CL2013001324A CL2013001324A CL2013001324A1 CL 2013001324 A1 CL2013001324 A1 CL 2013001324A1 CL 2013001324 A CL2013001324 A CL 2013001324A CL 2013001324 A CL2013001324 A CL 2013001324A CL 2013001324 A1 CL2013001324 A1 CL 2013001324A1
Authority
CL
Chile
Prior art keywords
kit
chemotherapeutic agents
treat cancer
additional chemotherapeutic
additional
Prior art date
Application number
CL2013001324A
Other languages
English (en)
Inventor
Joseph Anand Reddy
Christopher Paul Leamon
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CL2013001324A1 publication Critical patent/CL2013001324A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2013001324A 2010-11-12 2013-05-13 Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer. CL2013001324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41327510P 2010-11-12 2010-11-12

Publications (1)

Publication Number Publication Date
CL2013001324A1 true CL2013001324A1 (es) 2014-05-16

Family

ID=46048353

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013001324A CL2013001324A1 (es) 2010-11-12 2013-05-13 Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
CL2013001322A CL2013001322A1 (es) 2010-11-12 2013-05-13 Metodo para tratar un cancer tal como cancer de ovario, endometrio o pulmon, que comprende las etapas de administrar ec145 y uno o mas agentes quimioterapeuticos como taxano, docetaxel y paclitaxel, estando ambos componentes en contenedores esteriles; y kit que comprende ec145 y uno o mas agentes quimioterapeuticos adicionales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2013001322A CL2013001322A1 (es) 2010-11-12 2013-05-13 Metodo para tratar un cancer tal como cancer de ovario, endometrio o pulmon, que comprende las etapas de administrar ec145 y uno o mas agentes quimioterapeuticos como taxano, docetaxel y paclitaxel, estando ambos componentes en contenedores esteriles; y kit que comprende ec145 y uno o mas agentes quimioterapeuticos adicionales.

Country Status (16)

Country Link
US (3) US8987281B2 (es)
EP (2) EP2638395A4 (es)
JP (2) JP2013542263A (es)
KR (2) KR20130140033A (es)
CN (2) CN103403552B (es)
AU (2) AU2011325982C1 (es)
BR (2) BR112013011590A2 (es)
CA (2) CA2817219A1 (es)
CL (2) CL2013001324A1 (es)
EA (2) EA026168B1 (es)
HK (1) HK1189272A1 (es)
IL (2) IL226246A0 (es)
MX (2) MX2013005196A (es)
SG (2) SG190245A1 (es)
WO (2) WO2012065085A1 (es)
ZA (2) ZA201304226B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
JP5690589B2 (ja) 2007-06-25 2015-03-25 エンドサイト・インコーポレイテッドEndocyte, Inc. 親水性スペーサーリンカーを含有する結合体
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BR112013011590A2 (pt) 2010-11-12 2019-09-24 Endocyte Inc método de tratamento de câncer
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
WO2015077303A1 (en) 2013-11-19 2015-05-28 Purdue Research Foundation Patient selection method for inflammation
PT3134123T (pt) 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
CN103816548A (zh) * 2014-03-11 2014-05-28 北京林业大学 靶向亲水性聚合物-雷公藤甲素结合物
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
JP2017516760A (ja) * 2014-04-14 2017-06-22 エンドサイト・インコーポレイテッドEndocyte, Inc. 耐性がんを治療し、併用療法に用いるための薬物送達複合体
CN112638363A (zh) * 2018-08-31 2021-04-09 太阳医药工业有限公司 卡铂的肠胃外剂型

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
EP2060272A3 (en) * 2002-05-15 2009-05-27 Endocyte, Inc. Vitamin-mitomycin conjugates
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
DK1592457T3 (da) * 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
CN101239190B (zh) * 2003-01-27 2013-09-25 恩多塞特公司 维生素受体结合递药缀合物
JP2008537778A (ja) * 2005-03-30 2008-09-25 パーデュー・リサーチ・ファウンデーション 細胞の葉酸ビタミン受容体の定量化による癌予後診断法
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
US20070065449A1 (en) * 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
JP5690589B2 (ja) 2007-06-25 2015-03-25 エンドサイト・インコーポレイテッドEndocyte, Inc. 親水性スペーサーリンカーを含有する結合体
EP2349274A4 (en) * 2008-09-17 2014-12-17 Endocyte Inc CONJUGATES OF ANTIFOLATES BINDING THE FOLATE RECEPTOR
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
JP2013501224A (ja) 2009-07-31 2013-01-10 エンドサイト,インク. 葉酸を標的とした診断及び処置
BR112013011590A2 (pt) 2010-11-12 2019-09-24 Endocyte Inc método de tratamento de câncer

Also Published As

Publication number Publication date
AU2011325989C1 (en) 2015-04-23
US20120122893A1 (en) 2012-05-17
EA026168B1 (ru) 2017-03-31
SG190245A1 (en) 2013-06-28
KR20130140033A (ko) 2013-12-23
CA2817223A1 (en) 2012-05-18
BR112013011590A2 (pt) 2019-09-24
WO2012065085A4 (en) 2012-07-12
JP2013542264A (ja) 2013-11-21
CN103403552A (zh) 2013-11-20
HK1189272A1 (zh) 2014-05-30
AU2011325982A1 (en) 2013-04-18
WO2012065079A1 (en) 2012-05-18
EA025069B1 (ru) 2016-11-30
JP2013542263A (ja) 2013-11-21
SG190244A1 (en) 2013-06-28
IL226246A0 (en) 2013-07-31
EP2638395A4 (en) 2016-06-01
BR112013011659A2 (pt) 2016-08-02
US8883737B2 (en) 2014-11-11
AU2011325982C1 (en) 2015-08-20
AU2011325982B2 (en) 2014-10-09
EA201390695A1 (ru) 2013-12-30
ZA201304226B (en) 2017-11-29
CA2817219A1 (en) 2012-05-18
EA201390694A1 (ru) 2013-12-30
CN103282777A (zh) 2013-09-04
MX2013005194A (es) 2013-06-28
KR20130140032A (ko) 2013-12-23
IL226247A0 (en) 2013-06-27
EP2638395A1 (en) 2013-09-18
CL2013001322A1 (es) 2014-03-28
MX2013005196A (es) 2013-06-28
US8987281B2 (en) 2015-03-24
AU2011325989B2 (en) 2014-10-09
EP2638397A4 (en) 2016-06-01
US20130330326A1 (en) 2013-12-12
WO2012065085A1 (en) 2012-05-18
AU2011325989A1 (en) 2013-04-11
CN103403552B (zh) 2016-01-06
ZA201304225B (en) 2018-05-30
US20140066383A1 (en) 2014-03-06
EP2638397A1 (en) 2013-09-18
WO2012065079A4 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
CL2013001324A1 (es) Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
BR112013010988A2 (pt) composição fluída e uso
SMT201400146B (it) Morfolino pirimidine e loro uso in terapia
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BR112012003792A2 (pt) gel tópico, e, uso do gel tópico.
CL2012003643A1 (es) Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
IT1400425B1 (it) Modified snrnas for use in therapy.
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BRPI0914536A2 (pt) tiadiazoliloxifenilamidinas e o uso destas como fungicidas
BR112012002349A2 (pt) composto,e, uso do mesmo
BR112012004281A2 (pt) uso de metformina tratamento e prevenção de câncer
BR112013010171A2 (pt) combinação que consiste em um cartucho duplo e um misturador para uso do mesmo
CO6821883A2 (es) Nuevos moduladores y métodos para su uso
BRPI1007494A2 (pt) composto e uso do mesmo
DK3065759T3 (da) Immunosuppressive midler og deres anvendelse i terapi
BR112013010272A2 (pt) métodos analíticos e arranjos para uso nos mesmos
BR112013001423A2 (pt) método, método in vitro, uso e kit útil para realizar o método
BR112013015378A2 (pt) misturador dinâmico e seu uso
BR112014010739A2 (pt) agentes terapêuticos e uso dos mesmos
BR112012030927A2 (pt) fosfaplatinas e seu uso para o tratamento de cânceres
CO6781486A2 (es) Compuestos y su uso
BRPI0919794A2 (pt) dispositivo para uso intracorpóreo, e, composto
BR112014009476A2 (pt) refletor, iluminador e uso do iluminador
DK2883954T3 (da) Peptidbibliotek og anvendelse deraf
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso